Where Do We Stand in Targeted Therapy Against BRCA1/2 Deficient Cancers? DOI Creative Commons

Zoe Manuel-Epstein

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, Год журнала: 2024, Номер 8(8), С. 1 - 11

Опубликована: Авг. 20, 2024

Introduction: BRCA1 and BRCA2 are tumour suppressor genes that, when mutated, majorly increase the risk of cancer, particularly breast ovarian cancers. Cancer patients with BRCA mutations more likely to have aggressive forms cancer. Targeted therapy is a key component treatment for BRCA-deficient An important focus targeted synthetic lethality. Synthetic lethality loss viability from disruption two genes, but not either gene alone. The most established cancers poly (ADP-ribose) polymerase inhibitors (PARPi). This paper aims summarize advancements in against provide future directions. Methods: Relevant articles were found using search engines PubMed Google Scholar. Search terms relevant included "BRCA1", "BRCA2", "targeted therapies", "BRCA-deficient cancer", "synthetic lethality". Results: PARPi widely used clinical settings only approved by FDA use. exploits HR pathway cells trapping PARP at sites DNA damage, obstructing replication machinery, generating an accumulation DSBs, leading cell death. In addition PARPi, there has been further research into use other lethal interactors approaches target cancers, such as RAD52 inhibitors, FANCD2 immunotherapy, FEN1 APE2 PLK1 Damage Response Kinase RNF168 inhibitors. Discussion Conclusion: One major limitation rapid development resistance. Future steps must be taken overcome resistance improve sensitivity finding therapies alone create synergistic therapy. sum, ongoing BRCA-targeted occurring, efficacy will patient outcomes quality life.

Язык: Английский

Where Do We Stand in Targeted Therapy Against BRCA1/2 Deficient Cancers? DOI Creative Commons

Zoe Manuel-Epstein

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, Год журнала: 2024, Номер 8(8), С. 1 - 11

Опубликована: Авг. 20, 2024

Introduction: BRCA1 and BRCA2 are tumour suppressor genes that, when mutated, majorly increase the risk of cancer, particularly breast ovarian cancers. Cancer patients with BRCA mutations more likely to have aggressive forms cancer. Targeted therapy is a key component treatment for BRCA-deficient An important focus targeted synthetic lethality. Synthetic lethality loss viability from disruption two genes, but not either gene alone. The most established cancers poly (ADP-ribose) polymerase inhibitors (PARPi). This paper aims summarize advancements in against provide future directions. Methods: Relevant articles were found using search engines PubMed Google Scholar. Search terms relevant included "BRCA1", "BRCA2", "targeted therapies", "BRCA-deficient cancer", "synthetic lethality". Results: PARPi widely used clinical settings only approved by FDA use. exploits HR pathway cells trapping PARP at sites DNA damage, obstructing replication machinery, generating an accumulation DSBs, leading cell death. In addition PARPi, there has been further research into use other lethal interactors approaches target cancers, such as RAD52 inhibitors, FANCD2 immunotherapy, FEN1 APE2 PLK1 Damage Response Kinase RNF168 inhibitors. Discussion Conclusion: One major limitation rapid development resistance. Future steps must be taken overcome resistance improve sensitivity finding therapies alone create synergistic therapy. sum, ongoing BRCA-targeted occurring, efficacy will patient outcomes quality life.

Язык: Английский

Процитировано

1